Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-A3055 |
| Synonyms | |
| Therapy Description |
BGB-A3055 is a monoclonal antibody that targets CCR8 expressed on regulatory T-cells and inhibits downstream signaling, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-A3055 | BGBA3055|BGB A3055 | CCR8 Antibody 13 | BGB-A3055 is a monoclonal antibody that targets CCR8 expressed on regulatory T-cells and inhibits downstream signaling, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05935098 | Phase I | BGB-A3055 + Tislelizumab BGB-A3055 | A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | AUS | 2 |